loading page

Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic
  • Ahmet Emre EşkazanOrcid
Ahmet Emre Eşkazan
Orcid
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine
Author Profile

Peer review status:ACCEPTED

08 Apr 2020Submitted to British Journal of Clinical Pharmacology
11 Apr 2020Submission Checks Completed
11 Apr 2020Assigned to Editor
12 Apr 2020Reviewer(s) Assigned
15 Apr 2020Review(s) Completed, Editorial Evaluation Pending
20 Apr 2020Editorial Decision: Revise Major
24 Apr 20201st Revision Received
27 Apr 2020Submission Checks Completed
27 Apr 2020Assigned to Editor
27 Apr 2020Review(s) Completed, Editorial Evaluation Pending
27 Apr 2020Editorial Decision: Accept

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myeloid leukemia (CML), and currently in patients with CML in chronic phase (CML-CP) the first-line treatment is based on BCR-ABL targeted therapy with TKIs [1]. Although generally well tolerated, all BCR-ABL TKIs can be associated with hematologic and non-hematologic toxicities [2]. Most of the patients with CML-CP continue receiving TKIs, unless there is lack of optimal response and/or serious toxicities.